- cafead Jan 24, 2020 at 11:02: AM
via Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
article source
article source
-
Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page
Upcoming events – Genmab's route to market, and late-stage data for Zogenix
- Thread starter cafead
- Start date
<
Similar threads